An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead

被引:9
|
作者
Valipour, Mehdi [2 ]
Irannejad, Hamid [1 ]
Keyvani, Hossein [3 ]
机构
[1] Mazandaran Univ Med Sci, Fac Pharm, Dept Med Chem, Sari 4815733971, Iran
[2] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran 1134845764, Iran
[3] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran 1134845764, Iran
关键词
Coronavirus pandemics; SARS-CoV-2; anti-COVID-19drugs; monoclonal antibodies; small molecules; POPULATION-GENETICS; POTENTIAL TREATMENT; SARS-COV-2; BARICITINIB; INHIBITORS; EVOLUTION;
D O I
10.1021/acsptsci.3c00121
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The appearance of several coronavirus pandemics/epidemicsduringthe last two decades (SARS-CoV-1 in 2002, MERS-CoV in 2012, and SARS-CoV-2in 2019) indicates that humanity will face increasing challenges fromcoronaviruses in the future. The emergence of new strains with similartransmission characteristics as SARS-CoV-2 and mortality rates similarto SARS-CoV-1 (& SIM;10% mortality) or MERS-CoV (& SIM;35% mortality)in the future is a terrifying possibility. Therefore, getting enoughpreparations to face such risks is an inevitable necessity. The presentstudy aims to review the drug achievements and challenges in the fightagainst SARS-CoV-2 with a combined perspective derived from pharmacology,pharmacotherapy, and medicinal chemistry insights. Appreciating allthe efforts made during the past few years, there is strong evidencethat the desired results have not yet been achieved and research inthis area should still be pursued seriously. By expressing some pessimisticpossibilities and concluding that the drug discovery and pharmacotherapyof COVID-19 have not been successful so far, this short essay triesto draw the attention of responsible authorities to be more preparedagainst future coronavirus epidemics/pandemics.
引用
收藏
页码:1248 / 1265
页数:18
相关论文
共 50 条
  • [21] Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters
    Telbisz, Agnes
    Ambrus, Csilla
    Mozner, Orsolya
    Szabo, Edit
    Varady, Gyorgy
    Bakos, Eva
    Sarkadi, Balazs
    Ozvegy-Laczka, Csilla
    PHARMACEUTICS, 2021, 13 (01) : 1 - 18
  • [22] Anti-COVID-19 drugs, COVID-19 and anesthetics - The challenge for anesthesiologists
    Garg, Rakesh
    Yadav, Pratishtha
    JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 : 140 - 141
  • [23] Research and development of Chinese anti-COVID-19 drugs
    Ji, Xiwei
    Meng, Xiangrui
    Zhu, Xiao
    He, Qingfeng
    Cui, Yimin
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (12) : 4271 - 4286
  • [24] Protective features of anti-COVID-19 immune response
    Diem, Gabriel
    Jaeger, Michael
    Dichtl, Stefanie
    Bauer, Angelika
    Lass-Floerl, Cornelia
    Reindl, Markus
    Wilflingseder, Doris
    Posch, Wilfried
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 12 - 12
  • [25] Research and development of Chinese anti-COVID-19 drugs
    Xiwei Ji
    Xiangrui Meng
    Xiao Zhu
    Qingfeng He
    Yimin Cui
    ActaPharmaceuticaSinicaB, 2022, 12 (12) : 4271 - 4286
  • [26] Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
    Liu, Dongling
    Zeng, Xiang
    Ding, Zufeng
    Lv, Fenghua
    Mehta, Jawahar L.
    Wang, Xianwei
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [27] Progress in the Research and Development of Anti-COVID-19 Drugs
    Huang, Lianzhou
    Chen, Yuanqiu
    Xiao, Ji
    Luo, Weisheng
    Li, Feng
    Wang, Yuan
    Wang, Yiliang
    Wang, Yifei
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [28] Isoquercetin as an Anti-Covid-19 Medication: A Potential to Realize
    Mbikay, Majambu
    Chretien, Michel
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting
    Brady, Oliver J.
    Hofmann, Barbara
    Colon-Gonzalez, Felipe J.
    Gibb, Rory
    Lowe, Rachel
    Tsarouchi, Gina
    Harpham, Quillon
    Lumbroso, Darren
    Lan, Phan Trong
    Nam, Vu Sinh
    LANCET INFECTIOUS DISEASES, 2023, 23 (02): : 144 - 146
  • [30] CNS penetration of potential anti-COVID-19 drugs
    Peter J. Richardson
    Silvia Ottaviani
    Alessandro Prelle
    Justin Stebbing
    Giacomo Casalini
    Mario Corbellino
    Journal of Neurology, 2020, 267 : 1880 - 1882